Review Pembrolizumab (Keytruda): CADTH Reimbursement Advice: Indication: Together with chemotherapy, to the therapy of Grownup individuals with domestically recurrent unresectable or metastatic triple-damaging breast cancer who may have not gained prior chemotherapy for metastatic ailment and whose tumours express programmed mobile Demise-ligand 1